loader2
Partner With Us NRI

Aurobindo Pharma Ltd share Price Today

Company details

1,165.05
1,212.00
582.15
1,190.20
6M Return 15.65%
1Y Return 94.24%
Mkt Cap.(Cr) 68,264.82
Volume 415,670
Div Yield 0.62%
OI
-
OI Chg %
-
Volume 415,670

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Revenues beat but margins still below par..
About The Stock

    Aurobindo is a significant global generics player with 28 manufacturing facilities, including eight key formulations facilities in India and abroad along with three R&D centres. The current employee strength is more than 8000, which includes more than 750 scientists.

    • Q3FY23: US formulations constitute (46.8%) of revenues followed by Europe (26.6%), APIs (14.9%), RoW (7.8%) & ARV (3.9%)
    • Aurobindo is setting up a plant for production of Penicillin-G with capacity of 15,000 MT for ₹ 1850 crore, under the PLI scheme
Q3FY23

    Substantial revenue beat across regions. Margins in line.

    • Revenues grew 6.7% YoY to ₹ 6407 crore due to strong performance in the US as well as Europe
    • EBITDA de-grew 6.1% YoY to ₹ 954.5 crore while EBITDA margins de-grew 203 bps to 14.9%
    • Adjusted PAT declined 13.7% YoY to ₹ 492 crore  

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Aurobindo Pharma announced Q3FY24 results:

  • Revenue from Operations increased by 14.7% YoY to Rs 7,352 crore with growth seen across multiple businesses.
  • US formulations (excluding Puerto Rico) revenue increased by 28.9% YoY to Rs 3,756 crore (USD 451 million).
  • Europe formulation revenue increased by 1.6% YoY to Rs 1,728 crore (EUR 193 million).
  • Growth Markets revenue increased by 25.6% YoY to Rs 627 crore (USD 75 million).
  • ARV revenue decreased by 28.6% YoY to Rs 179 crore (USD 22 million).
  • API revenue grew by 7.1% YoY to Rs 1,022 crore (USD 123 million).
  • EBITDA before Forex and Other income stood at Rs 1,601 crore; EBITDA margin of 21.8%.
  • Research & Development (R&D) spend stood at Rs 398 crore, 5.4% of revenues (vs. Q2 FY24: 4.2%).
  • Received final approval for 16 ANDAs including 7 specialty & injectable products from the USFDA.
  • Net Profit after Share of Profit/Loss of JV and minority interest at Rs 936 crore, vs. Rs 491 crore in Q3FY23.
  • Basic & Diluted EPS grew by 91.4% YoY to Rs 16.04 per share.
  • Board has approved interim dividend @ 150% i.e. Rs 1.5 per equity share of Rs 1/- for FY24.

Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We are very pleased with the considerable progress we have made in our operations, and the cost efficiencies we have achieved, this quarter’s highest ever sales and EBITDA reflect the same. With our continued focus on developing a strong pipeline and driving the commercialization of our key projects, we are confident of our growth trajectory in the months ahead.”

Result PDF

View Other Company Results

Aurobindo Pharma Ltd shares SWOT Analysis

Strengths (9)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Company with high TTM EPS Growth
  • New 52 week high today

Weakness (5)

  • Promoters increased pledged shares QoQ
  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years

Opportunity (2)

  • Highest Recovery from 52 Week Low
  • RSI indicating price strength

Threats (2)

  • Companies with growing costs YoY for long term projects
  • Red Flags: Firms linked to ongoing regulatory investigations/legal cases

Resistance and support

R1 1,221.3
R2 1,240.1
R3 1,268.2
Pivot

1,193.15

S1 1,174.3
S2 1,146.2
S3 1,127.4
EMA SMA
1,144.4
1,112.3
1,073.9
988.5
1,140.0
1,099.1
1,088.2
1,000.6
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
SOCIETE GENERALE Block Purchase 2024-01-25 1160.1 1484323 BSE
MARSHALL WACE INVESTMENT STRATEGIES - EUREKA FUND Block Purchase 2024-01-25 1160.1 106480 BSE
MARSHALL WACE INVESTMENT STRATEGIES EUREKA FUND Block Purchase 2024-01-25 1160.1 53641 NSE
Name Category Shares
K NITYANANDA REDDY PROMOTER 4.33%
KIRTHI REDDY KAMBAM PROMOTER 3.49%
M SIVAKUMARAN PROMOTER 2.47%
KAMBAM SPOORTHI PROMOTER 1.19%
RPR SONS ADVISORS PRIVATE LIMITED, MRS.P.SUNEELA RANI (JOINTLY HOLDING) PROMOTER 33.51%
AXIS CLINICALS LIMITED, TRIDENT CHEMPHAR LIMITED, RPR SONS ADVISORS PVT.LTD. (JOINTLY HOLDING) PROMOTER 2.85%
VENKATA RAMPRASAD REDDY PENAKA PROMOTER 3.07%

OUR RESEARCH VIEW

Investment recommendation
Revenues beat but margins still below par..
Call Date
21 Feb 2023
Entry Price 464.00
Target Price 525.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Aurobindo Pharma Ltd Stocks COMPARISON

Financials( in Cr) Aurobindo Pharma Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Zydus Lifesciences Ltd Divis Laboratories Ltd
Price 1,165.05 1,531.40 1,399.05 1,051.40 3,910.75
% Change 0.57 0.26 -0.54 5.45 0.47
Mcap Cr 68,264.82 367,434.16 112,954.68 105,795.44 103,818.29
Revenue TTM Cr 24,855.38 43,885.68 15,790.60 17,237.40 7,767.51
Net Profit TTM Cr 1,927.65 8,560.84 2,513.47 1,997.30 1,823.38
PE TTM 25.07 39.15 26.62 28.83 75.36
1 Year Return 94.24 64.73 52.99 106.95 24.01
ROCE 9.18 16.79 14.76 16.25 19.30
ROE 7.50 16.46 10.66 14.05 14.89
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 26,839.85 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 45,096.27 -32,431.93
LAST 3M 105,135.14 -41,239.38
LAST 6M 172,248.08 48,806.90
LAST 12M 264,707.07 127,969.33
Aurobindo Pharma to table results

May 17, 2024 l BSE Announcement

Aurobindo Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates

May 17, 2024 l NSE Announcement

Aurobindo Pharma Limited - Board Meeting

May 16, 2024 l NSE Announcement

Date Action Type Ratio
Feb 20, 2024 Dividend 150
Nov 20, 2023 Dividend 300
Feb 17, 2023 Dividend 300

Aurobindo Pharma Ltd Information

Stock PE (TTM)
25.07
Promoter Holding
51.83%
Book Value
481.088
ROCE
9.18%
ROE
7.5%
Description
  • Aurobindo Pharma is a distinguished name in the pharmaceutical industry. It was incorporated in 1986, and its headquarters is located in Hyderabad. As of 31 December 2021, it reported a net income of Rs 604.73 crore. The prominent faces in Aurobindo Pharma management are—Mr K Raghunathan, Mr K Nityananda Reddy, Dr M. Sivakumaran, Mr P. V Ram Prasad Reddy, and a few more. Aurobindo Pharma’s valuation on the stock exchange is Rs 30,636 crore. 

    The company is listed on both the stock exchanges of India, that is NSE and BSE. It is traded under the symbol AURO PHARMA. 

    The company is primarily into the development, manufacturing, and supply of active pharmaceutical ingredients, generic pharmaceuticals, and branded speciality pharmaceuticals. Some key offerings in its product portfolio cater to/include antibiotics, central nervous system, anti-diabetics, gastroenterological, anti-retroviral, and cardiovascular. The company currently supplies its products to more than 150 countries. Its subsidiary company list includes Aurolife Pharma LLC, APL Healthcare, Auro Peptides Ltd, Auronext Pharma Pvt. Ltd. and a few more. 

    Now, if you dive into the company’s financials, you will find the following.

    Aurobindo Pharma’s price-to-equity ratio or PE ratio (6.13) and price-to-book ratio or PB ratio (1.49) are better than the industry’s average. The same is the case with revenue and net income. Over the past five years, Aurobindo Pharma’s revenue and income have grown at an annual rate of 15.2% and 21.38%, respectively. For the same period, the industry’s average income and revenue growth rates were 6.94% and 8.25%, respectively. Aurobindo Pharma’s total liabilities declined by Rs 467.41 crore compared to the financial year 2020. Even after reducing the liabilities, the company cash flow statement shows a free cash flow of Rs 1455.11 crore in FY20-21. 

    On 20 May 2022, the Aurobindo Pharma share price on NSE closed at Rs 557.95. It was 6.71% higher than the previous day’s closing price. The last 52 weeks’ movement of Aurobindo Pharma Ltd.’s share price on the stock market saw a high of Rs 1,043.10 and a low of Rs 520.85. Investing in Aurobindo Pharma shares carries a low amount of risk since its price volatility is 1.95x that of the Nifty.  The key names in its peers’ list are Cipla Ltd., Torrent Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., and Dr Reddy’s Laboratories Ltd.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, 500038

Tel : 91-40-23736370
Email : cs:aurobindo.com; investorgrievances:aurobindo.com
Website : http://www.aurobindo.com
Registrar

KFin Techologies Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 524804
NSE Code : AUROPHARMA
Book Closure Date (Month) : Aug
BSE Group : A
ISIN : INE406A01037

FAQ’s on Aurobindo Pharma Ltd Shares

You can buy Aurobindo Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Aurobindo Pharma Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 17, 2024 03:57 PM the closing price of Aurobindo Pharma Ltd was Rs.1,165.05.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 17, 2024 03:57 PM, the market cap of Aurobindo Pharma Ltd stood at Rs. 68,264.82.

The latest PE ratio of Aurobindo Pharma Ltd as of May 17, 2024 03:57 PM is 25.07

The latest PB ratio of Aurobindo Pharma Ltd as of May 17, 2024 03:57 PM is 0.41

The 52-week high of Aurobindo Pharma Ltd share price is Rs. 1,190.20 while the 52-week low is Rs. 582.15

According to analyst recommendations, Aurobindo Pharma Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app